The Biosynthetic Monophosphoryl Lipid A Enhances the Therapeutic Outcome of Antibiotic Therapy in Pneumococcal Pneumonia.
Streptococcus pneumoniae
Toll-like receptor
adjunct therapy
amoxicillin
bacterial pneumonia
Journal
ACS infectious diseases
ISSN: 2373-8227
Titre abrégé: ACS Infect Dis
Pays: United States
ID NLM: 101654580
Informations de publication
Date de publication:
13 08 2021
13 08 2021
Historique:
pubmed:
15
7
2021
medline:
10
9
2021
entrez:
14
7
2021
Statut:
ppublish
Résumé
Alternative treatment strategies against bacterial infections are required to decrease the use of antibiotics. This study tested the hypothesis that stimulation of the innate immune receptor Toll-like receptor 4 can be combined with antibiotics to improve the treatment of invasive pneumonia. The efficacy of the biosynthetic monophosphoryl lipid A (MPLA), a clinically approved Toll-like receptor 4 activator, was tested in a mouse model of
Identifiants
pubmed: 34260199
doi: 10.1021/acsinfecdis.1c00176
doi:
Substances chimiques
Anti-Bacterial Agents
0
Lipid A
0
monophosphoryl lipid A
MWC0ET1L2P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM